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6944 | Chem. Sci., 2019, 10, 6944–695cell uptake off to on responsive
NIR-AZA fluorophores: applications toward
intraoperative fluorescence guided surgery†
Dan Wu, a Harrison C. Daly,a Marco Grossi,a Emer Conroy,b Bo Li,b
William M. Gallagher,b Robert Elmes c and Donal F. O'Shea *a
The use of NIR-fluorescence imaging to demarcate tumour boundaries for real-time guidance of their
surgical resection has a huge untapped potential. However, fluorescence imaging using molecular
fluorophores, even with a targeting biomolecule attached, has a major shortcoming of signal
interference from non-specific background fluorescence outside the region of interest. This poor
selectivity necessitates prolonged time delays to allow clearance of background fluorophore and
retention within the tumour prior to image acquisition. In this report, an innovative approach to
overcome this issue is described in which cancer targeted off to on bio-responsive NIR-fluorophores are
utilised to switch-on first within the tumour. Bio-responsive cRGD, iRGD and PEG conjugates have been
synthesised using activated ester/amine or maleimide/thiol couplings to link targeting and fluorophore
components. Their off to on emission responses were measured and compared with an always-on non-
responsive control with each bio-responsive derivative showing large fluorescence enhancement values.
Live cell imaging experiments using metastatic breast cancer cells confirmed in vitro bio-responsive
capabilities. An in vivo assessment of MDA-MB 231 tumour imaging performance for bio-responsive and
always-on fluorophores was conducted with monitoring of fluorescence distributions over 96 h. As
anticipated, the always-on fluorophore gave an immediate, non-specific and very strong emission
throughout whereas the bio-responsive derivatives initially displayed very low fluorescence. All three
bio-responsive derivatives switched on within tumours at time points consistent with their conjugated
targeting groups. cRGD and iRGD conjugates both had effective tumour turn-on in the first hour, though
the cRGD derivative had superior specificity for tumour over the iRGD conjugate. The pegylated
derivative had similar switch-on characteristics but over a much longer period, taking 9 h before
a significant emission was observable from the tumour. Evidence for in vivo active tumour targeting was
obtained for the best performing cRGD bio-responsive NIR-AZA derivative from competitive binding
studies. Overall, this cRGD-conjugate has the potential to overcome the inherent drawback of targeted
always-on fluorophores requiring prolonged clearance times and shows excellent potential for clinical
translation for intraoperative use in fluorescence guided tumour resections.Introduction
Intraoperative uorescence imaging to guide surgical resections
in real-time has huge untapped potential. Advantages lie in its
ease of use, enhanced safety prole over radiolabelling and the
ability to acquire image data in real-time during surgicalephen's Green, Dublin 2, Ireland. E-mail:
nce, Conway Institute, University College
rsity Human Health Institute, Maynooth
n (ESI) available: All experimental
ages, spectroscopy and analytical data
6
procedures.1 Currently indocyanine green (ICG) is the sole
clinically approved near infrared red (NIR) uorophore.2 Clin-
ical uses include vascularisation assessments during recon-
structive3 and bowel anastomoses4 surgeries and lymph node
mapping in digestive tract,5 cervical6 and breast7 tissues. Due to
its non-specicity and very short in vivo half-life, its use as an
agent to demarcate tumour boundaries for surgical resection is
limited to hepatocellular carcinoma of the liver.8,9
As a result, new classes of NIR-uorophore have recently
emerged, several of which are bio-conjugated to enhance their
affinity for specic cancer types.10 However, a remaining
complexity for in vivo uorescence imaging using molecular
uorophores exists. Following intravenous administration, u-
orophore distributes to all vascularised regions within seconds,
resulting in a strong non-specic uorescence. ThisThis journal is © The Royal Society of Chemistry 2019
Fig. 2 Lysosomal off/on bio-responsive NIR-AZA fluorophore 1.























































































View Article Onlinenecessitates an unpredictable time delay to allow background
uorophore clearance, following which imaging is achievable if
sufficient uorophore is retained in the region of interest (ROI)
(Fig. 1a). This limitation is irrespective of whether the uo-
rophore alone is used or if conjugated to a targeting group (e.g.
antibody), as an initial broad distribution will still occur. The
time between administration and imaging depends on several
parameters such as rates of accumulation and clearance from
both the ROI and surrounding tissues and elimination from the
body via metabolic and excretion pathways. Each of these
factors can be inuenced by the structure of uorophore itself
and by groups conjugated to it, but a time lag before imaging is
unavoidable. To provide sufficient contrast for imaging, it is
necessary to identify an optimal time point at which
a maximum quantity of uorophore is retained in the ROI with
a minimum remaining in the surrounding tissues. For example,
antibody conjugated uorophores have been adopted in recent
clinical trials for visualising breast and colorectal cancers uti-
lising labelled bevacizumab and carcinoembryonic antigen
(CEA) respectively.11,12 Yet in spite of using these expensive
cancer specic antibody technologies, uorescence images
could only be acquired between two and four days post
administration. The prolonged waiting period to achieve suffi-
cient tissue contrast is due to the very long biological half-lives
of antibody labelled agents. This time delay adds signicant
uncertainty to their practical use and raises doubts as to
whether all of the cancer would then be detectable by the low
levels of remaining uorophore. In effect, what makes large
molecular weight antibodies attractive for sustained drug
delivery, can work against them when used for the delivery of
contrast agents (Fig. 1a).
Thus, for rapid and accurate intraoperative imaging inno-
vative alternative approaches are needed to enhance target-to-
background signal ratio at early stages following uorophore
introduction. One plausible solution is to exploit a mechanism
of selective uorescence quenching in the background areas,
whilst rst establishing the emitting potential of the uo-
rophore in the ROI (Fig. 1b). This overcomes the issue of waitingFig. 1 Potential of bio-responsive NIR-fluorescence imaging. (a)
Sequence following i.v. administration of always-on fluorophore. (b)
Sequence following i.v. administration of bio-responsive fluorophore
(red indicates fluorescence blue indicated bio-responsive fluorophore
turned off).
This journal is © The Royal Society of Chemistry 2019for background clearance and allows observation of dynamic
tissue accumulation in real-time during the course of the
surgical procedure. While beyond the scope of this work, it may
become feasible that dynamic images are recorded continu-
ously, with tissue classications determined using in-line so-
ware image analysis.
In our previous work, we have shown that bio-responsive
NIR-AZA uorophore 1 performs as an excellent probe capable
of real-time continuous imaging of fundamental cellular
processes such as endocytosis, lysosomal trafficking and efflux
(Fig. 2).13a Specically, the highly photostable NIR uorescent
probe 1 has off/on uorescence switching controlled by
a reversible phenol/phenolate interconversion (Fig. 2). Emis-
sion from the probe was shown to be highly selective for cellular
lysosomes and, as the off/on switching mechanism is reversible,
it is capable of real-time continuous imaging of lysosomal
trafficking in 3D or 4D over prolonged time periods without
perturbing normal cellular function.14 Preliminary in vivo
imaging in a mouse tumour xenogra model showed good
tumour discrimination 24 h post i.v. injection of 1 with no
observable toxicity.13a These positive in vitro and in vivo features
are good indicators that bio-responsive NIR-AZA uorophores
warrant further investigation for translation towards clinical
use in uorescence-guided surgery. In recent preclinical tests,
always-on NIR-AZA uorophores have shown their potential for
lymph node mapping and ureter identication using clinical
instrumentation.15 In this report, we describe the synthesis,
photophysical characterisation, in vitro and in vivo imaging
assessment of bio-responsive NIR-AZA uorophores conjugated
to cyclic-RGD peptide sequences and polyethylene glycol poly-
mer acting as active or passive targeting agents respectively.Chem. Sci., 2019, 10, 6944–6956 | 6945
Fig. 3 cRGD and iRGD bio-responsive NIR-AZAs 2 and 3. Conjugation linkages highlighted in blue.























































































View Article OnlineBreast cancer is a key health concern for women, with over
twomillion new cases diagnosed worldwide annually. Screening
programs have resulted in most breast cancers being identied
in the early stages with over 80% of breast cancer patients
undergoing surgery as part of their treatment. Numerous trials
have shown that for patients with between zero and three node
metastases, breast-conserving surgery has similar or superior
outcomes to mastectomy.16 As tumour-free surgical margins are
critical to the success of breast-conserving surgery, utilising
uorescence guidance to improve surgical outcomes could have
signicant patient benet.
Integrins are membrane bound cell adhesion receptors
important for cell–cell and cell-extracellular matrix (ECM)
interactions. They act as transmembrane linkers between
extracellular ligands such as ECM proteins, growth factors,
matrix degrading proteins and the cytoskeleton, which serves to
modulate various essential signalling pathways in most cells.17
Integrins such as avb3 and avb5 (among others) are known to
play a key role in tumour angiogenesis and are associated with
the metastasis of solid tumours.18 Of the integrins, avb3 is one
of the most studied as it is the most prevalent integrin involved
in the regulation of angiogenesis and is widely expressed on
tumour blood vessels.19 Over-expression of avb3 integrin has
been associated with increased tumour growth in breast cancer
and it has been shown that the activation of avb3 is a contrib-
uting factor for metastasis in breast cancer models.20 The tri-
peptide arginine–glycine–aspartic acid (RGD) sequence can
recognise and bind anb3 and avb5 integrins and promote
cellular internalisation with conjugates of the more stable cyclic
variant c(RGDfK) being widely investigated as a selectivity
enhancer for tumour therapies and diagnostics.21 The related
iRGD peptide sequence (cCRGDKGPDC) has been reported to
provide both specic integrin targeting and increased tumour
uptake and penetration. It contains the RGD motif, which
mediates binding to the endothelial cell membrane expressing
the av integrins but upon proteolytic cleavage a second6946 | Chem. Sci., 2019, 10, 6944–6956neuropilin-1 (NRP-1) binding motif (CRGDK) is revealed to
promote internalisation.22 Both RGD and iRGD conjugates have
been investigated to improve drug selectivity with chemother-
apeutic conjugates such as RGD-doxorubicin and RGD-
paclitaxel showing promising preclinical results in breast
carcinoma mouse models.23 RGD conjugates for uorescent
imaging using always-on probes has been explored in several
preclinical models including breast cancers.24
For this study we have chosen one cRGD (c[RGDfK(PEG-
PEG)]) and one iRGD (cCRGDKGPDC) peptide sequence for
conjugation to the bio-responsive NIR-AZA imaging platform. It
was hoped that these low molecular weight peptides would
promote rapid uptake and switch-on of emission preferentially
within tumours allowing a high tumour to background ratio
(TBR) to be established without waiting for prolonged clearance
times. In practice, it is envisaged that they would be adminis-
tered and visualised intraoperatively, thereby not impeding the
normal surgical or hospital workow.Results and discussion
Incomplete tumour removal during surgical resection is closely
related to cancer reoccurrence and patient survival rates. A
major challenge in achieving cancer free margins is to fully
distinguish between all of the cancerous growth and normal
tissue during surgery. While high denition images obtained by
PET, CT or MRI scans identify and diagnose tumour growths
prior to surgery, such images are not overly useful to guide
surgical resection during the operation. Currently, tumour
margins are typically assessed by visual assessment and
palpation of the tumour intraoperatively. However, the possi-
bility of micro-invasion of the surrounding tissues can make it
difficult to determine an adequate tumour-free excision margin.
In this report, we have developed synthetic routes to RGD
conjugated bio-responsive uorophores, examined their pho-
tophysical and in vitro cellular emission proles and tested theirThis journal is © The Royal Society of Chemistry 2019
Scheme 1 Synthesis of bio-responsive cRGD NIR-AZA conjugate 2. (a) Conditions for activated ester/amine coupling of 4 and 5. (b) 1H NMR
spectra of 4 and 2 with key methylene peaks (shown in blue) indicated (*CH2Cl2).























































































View Article Onlinein vivo tumour imaging performance using a human breast
tumour model in mice.
Synthesis and characterisation
Cell uptake responsive probes 2 and 3 were selected for
synthesis using activated ester/amine coupling to conjugate the
cRGD sequence and cysteine to maleimide addition for the
covalent linkage of the iRGD peptide sequence (Fig. 3). Two bio-
conjugation approaches were adopted to conrm synthetic
exibility of NIR-AZA bio-uorophores to functionalisation with
targeting moieties.
Synthesis of 2 required uorochrome 4 which has been
previously reported, though only in reaction with an amino-
pegylated polymer to produce 1 (Scheme 1).13a For this study,
the amino-pegylated substituted cRGD substrate 5 (cyclo[Arg-
Gly-Asp-D-Phe-Lys(PEG-PEG-NH2)]) was selected as it is known
to be an ideal construct for housing the integrin recognising
tripeptide sequence (Scheme 1a). The reaction of 4 and 5 inThis journal is © The Royal Society of Chemistry 2019DMSO at rt was followed by HPLC and 1H NMR which showed
a clean conversion to conjugate 2 in 4 h. Transformation of
activated ester 4 into conjugate 2 was clearly distinguishable by
the shi of the key methylene 1H NMR peak from 5.53 to
4.61 ppm (Scheme 1b). Purication of product was achieved
using preparative reverse phase HPLC and the structure
conrmed by high-resolution MS and NMR methods.
The generation of iRGD conjugate 3 rst required the
synthesis of the corresponding maleimide-substituted uoro-
chrome 7 (Scheme 2). This was readily achievable starting from
the previously reported derivative 6 which was subjected to the
nitration conditions of KHSO4/KNO3 at reux in CH3CN/H2O to
yield the o-nitro phenol substituted substrate 7.25 Synthesis of
iRGD peptide 8 followed literature procedures to produce
(cCRGDKGPDC) which was coupled with N-acetyl protected
cysteine, through the amine of the lysine residue, to provide the
nal thiol substituted peptide.26 Bio-conjugation via cysteine to
maleimide addition was efficiently achieved by reaction of 7Chem. Sci., 2019, 10, 6944–6956 | 6947
Scheme 2 Synthetic route to bio-responsive iRGD NIR-AZA conju-
gate 3.
Scheme 3 Synthesis of iRGD conjugated always-on NIR-AZA control
10.























































































View Article Onlinewith iRGD 8 in DMSO at rt for 30 min to produce the required
derivative 3 (Scheme 2). Product purication utilised prepara-
tive reverse phase HPLC with the structure conrmed by usual
analytical methods (ESI†).
To allow comparisons be made between bio-responsive and
non-responsive conjugates the iRGD substituted always-on
control 10 was synthesised. Conjugate 10 is similar in structure
to 3 but has the o-nitro phenol uorescence switching substit-
uent replaced by a water solubilizing alkylsulfonic acid group
(Scheme 3). The synthetic route adopted to make this control
utilised the reaction of known uorochrome 9 with peptide 8 to
produce 10.25 The cysteine/maleimide coupling proceeded
smoothly in phosphate buffered saline (PBS) at pH 7.2 with
iRGD conjugated 10 obtained in good yield (Scheme 3, ESI†).
To test the extent of advantage gained from utilising integrin
targeting RGD peptide conjugates such as 2 and 3 versus
a passive accumulating agent such as a PEG group, the pegy-
lated bio-responsive 1 was also included for testing in the study
as a comparative control (Fig. 2). This we envisaged would allow
a direct imaging performance evaluation between bio-
responsive uorophores using either active targeting peptides
or the passive enhanced permeability and retention (EPR) effect
of a PEG group.Photophysical properties
The photophysical properties of the bio-responsive uo-
rophores 2 and 3 and the always-on control 10 were studied in
solutions of Dulbecco's modied eagle's cell medium (DMEM)
containing 10% fetal bovine serum (FBS). Absorption and6948 | Chem. Sci., 2019, 10, 6944–6956emission wavelengths are listed in Table 1 and are, as would be
expected for the NIR-AZA class, in the 690–730 nm range. At pH
7.4 uorescence intensity of always-on 10 was 17- and 15-fold
greater than 2 and 3 respectively (Table 1). This illustrates both
the emissive potential of the peptide conjugates and the ability
to quench the bio-responsive derivatives in relevant biological
media (Table 1, spectra and inset).
In order to display the responsive nature and full emissive
potential of 2 and 3, their DMEM solutions were sequentially
acidied (Fig. 4a and b). This caused a successive increase in
emission intensity as acidity increased, with a maximum
intensity reached at approximately pH 4. Plotting the measured
data revealed pKa values of 4.9 for both 2 and 3 which is
consistent with the previously reported value of 4.6 for 1 (Fig. 4
insets, Fig. S1–S3†).13a This shows that the conjugating group
does not overly inuence the important p-nitro phenol
emission-controlling feature. While it is recognized that the
extracellular matrix of a solid tumour can be more acidic than
normal tissue, intracellular organelles such as late endosomes
and lysosomes are also acidic ranging between pH 4.5 and 5.5.27
Encouragingly, the measured uorescence enhancement factor
(FEF) for 2 and 3 between pH 7.2 and that of 4.5 (as found in
lysosomes) was 23 and 18 respectively (Fig. 4c). As such,
a switch-on of emission could be expected to occur both in theThis journal is © The Royal Society of Chemistry 2019




abs (nm) pH 7.2
lmax
abs (nm) pH 4.5
lmax
u (nm) FEF pH 7.4/4.5d,e
1 749 685 707 21 13a
2 755 693 713 23
3 757 696 716 18
10 705 703 733 1.0
a DMEM/10% FBS solutions with 4 mM TX-100. b To allow a common
comparison for each uorophore solution across a wide acidity range
4 mM Triton X 100 was included in each solution. c Fluorescence
spectra taken at 5 mM concentration, 2 (black spectra) 3 (grey spectra)
10 (red spectrum), inset shows expansion of spectra for 2 and 3.
d Fluorescence enhancement factor (FEF). e Fluorescence quantum
yields at pH 7.4 of 2 and 3 ¼ 0.16 and 0.18 respectively (ESI).
Fig. 4 Responsive emission characteristics of 2 and 3 (5 mM) in DMEM/
10% FBS solutions containing TX100. (a) Fluorescence spectra of 2 at
pH ranging from 8.0 (black) to 2.0 (red); inset sigmoidal plot fit of
integrated fluorescence intensity versus pH. (b) Fluorescence spectra
of 3 at pH ranging from 8.0 (black) to 2.0 (red); inset sigmoidal plot fit
of integrated fluorescence intensity versus pH. (c) Diagram repre-
senting FEF values from differing pH solutions of 2 (solid red bars) and
3 (crossed red bars).























































































View Article Onlinelocalised extracellular tumour microenvironment and upon
cancer cell uptake. As emission quenching in the off states of 2
and 3 at pH 7.2 is highly effective, good background to noise
differentials could be anticipated. In contrast, control uo-
rophore 10 showed no absorption or emission spectral changes
between pH 7.2 and 4.5 (Fig. S4†).
The next stage involved testing 2, 3 and control 10 in live cell
imaging using the epithelial human breast cancer cell line
MDA-MB 231 that is known to express membrane integrins
including avb3 and avb5. MDA-MB 231 is a highly aggressive
triple-negative cell line, with its invasiveness mediated by
proteolytic degradation of the extracellular matrix.28 The meta-
static invasive nature of MDA-MB 231 cells is closely associated
with large acidic vesicles (LAV) in which endocytosed extracel-
lular matrix can be digested by activated lysosomal proteinases
such as cathepsin.29 As these intracellular LAVs have a pH of
approximately 4, they also could activate the bio-responsive
uorophores upon cancer cell uptake in addition to lysosomes.In vitro live MDA-MB 231 cell imaging
With the responsive nature of 2 and 3 established, the potential
for translation of these constructs to real-time live cell imaging
was investigated. In order to illustrate the imaging effect of the
bio-responsive characteristics of 2 and 3 the always-on 10 was
also imaged as a positive control. For live MDA-MB 231 cell
experiments, chamber slide seeded cells were placed inThis journal is © The Royal Society of Chemistry 2019a wideeld microscope surrounded by an incubator to maintain
the temperature at 37 C and CO2 at 5%, following which an
imaging eld of view containing viable cells was chosen. The
cells were treated with either 2, 3 or 10 (1–5 mM) and time-lapse
NIR-uorescence and differential interference contrast (DIC)
images were acquired over 120 min. Image data showed that for
always-on 10, a uorescence specic to the plasma membrane
was rapidly observed within 15 min, which could be attributed
to its strong association with the cell membrane (Fig. 5a). As
expected, the endothelial-like morphology of the cell line is
distinguishable by its membrane lopodia projections which is
characteristic of its metastatic invasive phenotype (Movie S1†).Chem. Sci., 2019, 10, 6944–6956 | 6949
Fig. 5 DIC and fluorescencemicroscopy imaging of live MDA-MB 231
cells over time following treatment with 10 (5 mM). Images taken at (a)
15 min (b) 1 h and (c) 2 h. Scale bars ¼ 20 mm.
Fig. 6 DIC and NIR fluorescencemicroscopy imaging of live MDA-MB
231 over time following incubation with 2 (5 mM). Images taken at (a)
15 min (b) 1 h and (c) 2 h. Scale bars ¼ 20 mm.























































































View Article OnlineAer 60 min incubation, both cell membrane and intracellular
vesicle staining of the cytoplasm could be observed, both of
which persisted at 120 min (Fig. 5b and c). A wider eld of view
showing a larger number of cells and Z-stack images can be
seen in Fig. S5, S6 and Movie S2.†
Revealingly, the bio-responsive NIR-AZAs 2 showed no cell
membrane staining in the rst 15 min of incubation and only
following this time point could intracellular regions of uo-
rescence be observed (Fig. 6a). The intracellular punctate
staining pattern is consistent with those previously observed for
1 and are due to a selective bio-responsive switch-on of emission
within the acidic vesicles of the cytoplasm.13a,14 The images
revealed two distinct vesicle sizes, the smaller of which are
attributable to cellular lysosomes and the bigger LAVs specic
to the metastatic nature of MDA-MB 231 cells (Movie S3 and
S4†). At 60 and 120 min the intracellular uorescence intensity
increased, but at no point wasmembrane uorescence observed
(Fig. 6b, c and Movie S5†). This lack of plasma membrane
uorescence shows that 2 can translocate across the membrane6950 | Chem. Sci., 2019, 10, 6944–6956without uorescence being activated. A wider eld of view
showing a larger number of cells can be seen in Fig. S7.† Z-Stack
analysis of cells conrmed that regions of uorescence were
within the cytoplasm (Fig. S8 and Movie S6†). Similar results
were obtained from imaging experiments using bio-responsive
iRGD NIR-AZA 3 which can be seen in Fig. S9, S10 and Movie
S7.† In addition, similar results were obtained from imaging
experiments with HeLa Kyoto cells using bio-responsive 2which
can be seen in Movie S8.†
The different cell staining patterns between 10 and 2, 3 over
time shows the delity of the uorescence switching and the
potential signal to background contrast advantage of the bio-
responsive NIR-AZA probes. The next challenge of this work
was to examine if a preferential in vivo switch-on of bio-
responsive NIR-AZAs in cancerous tumour could allow both
early (due to initial switch-on) and later (due to retention of
switched on probe) stage discrimination of tumour from
background.In vivo tumour imaging
For this study, the human breast cancer cell line MDA-MB 231
was selected for its relevance to clinical forms of aggressive
breast cancers for which the rst line of treatment is oen
surgical resection. The ability of bio-responsive conjugates 1, 2
and 3 were tested using subcutaneous tumours grown in nude
mice. Fluorophore 10 was also included as a positive control in
the study to demonstrate the advantage of using off to on
responsive uorescence over a constant emission. It was
anticipated that 1, 2 and 3 would remain predominately uo-
rescent silent until tumour uptake occurred causing a uores-
cence signal modulation to on. Experimental measurement of
changes in tumor-to-background ratio (TBR) over time was the
preferred method to quantify differences between bio-
responsive and always-on uorophores. Pegylated bio-
responsive 1 was included to compare the turn-on time differ-
ences between passive PEG and the active integrin targeting of 2
and 3. The expectation being that the larger EPR dependent PEG
conjugate would be slower.
Each uorophore was subjected to in vivo analysis using
a standard dosing set at 2 mg kg1 delivered by i.v. tail vein
injection. Post injection, images were acquired initially at
regular intervals between 10 min and 9 h and thereaer less
frequently at 24, 48 and 96 h. The method used for image
analysis was consistent across all experiments with TBR values
calculated by measuring tumour ROI uorescence against an
average of three equally sized background ROI regions, two of
which were close to and one distant from the tumour
(Fig. S11†). In previously reported preclinical studies, when
imaging through the skin, a TBR ratio of two was shown to be
a clinically relevant threshold.24a,30 As such, we adopted this
value as a point of reference to compare result from different
uorophores and different time points for individual
uorophores.
For always-on iRGD control 10, from 10 to 60 min post i.v.
injection an immediate strong and non-specic uorescence
was observable throughout the animals, with no discernibleThis journal is © The Royal Society of Chemistry 2019
Fig. 7 Analysis of fluorescence images for always-on iRDG NIR-AZA 10 (10.1 nmol) over time (n ¼ 2). (a) Plot of TBR values at individual time-
points over 96 h, dashed red line indicating threshold value of 2. Values determined by ROI total fluorescence signal of tumour divided by an
averaged value of three independent background regions as measured by living image software v4.7. (b) Plot of tumour fluorescence intensity
over 96 h, inset shows expansion of 0–3 h. (c) Representative in vivo fluorescence images of 10 using a MDA-MB 231 subcutaneous tumour
model at different time points. First image shows selected tumour ROI (solid circle) and three background ROIs (dashed circles).























































































View Article Onlinebias for tumour as demonstrated by the measured TBRs of
below 1.3 (Fig. 7a). The TBR value marginally improved over the
following 2 h with a TBR value of 1.5 achieved at 3 h post
administration. While it is likely that 10 has begun to accu-
mulate at the tumour site, the cancerous ROI is not readily
distinguishable from the background uorescence (Fig. 7c, see
Fig. S12 in ESI† for additional time point images). By the 6 hFig. 8 Analysis of in vivo fluorescence imaging for bio-responsive RG
individual time-points over 96 h, dashed red line indicating threshold val
divided by an averaged value of three independent background region
rescence intensity over 96 h, inset shows expansion of 0–3 h. (c) Re
subcutaneous tumourmodel at different time points (scale bar identical to
three background ROIs (dashed circles).
This journal is © The Royal Society of Chemistry 2019time point the TBR had improved further to 1.9, though, it was
not until 24 h post administration that a TBR above 2 was ob-
tained. By this time, the overall uorescence intensity had
dropped approximately 75% fold from its peak (Fig. 7b). The
TBR value of 2 was maintained out to 48 h as the emission
intensity further decreased (90% of peak), and by 96 h it had
fallen below the threshold. This sequence of TBR values comesD NIR-AZA 2 (13.2 nmol) over time (n ¼ 4). (a) Plot of TBR values at
ue of 2. Values determined by ROI total fluorescence signal of tumour
s as measured by living image software v4.7. (b) Plot of tumour fluo-
presentative in vivo fluorescence images of 2 using a MDA-MB 231
Fig. 9 and 10). First image shows selected tumour ROI (solid circle) and
Chem. Sci., 2019, 10, 6944–6956 | 6951
Fig. 9 Analysis of in vivo fluorescence imaging for bio-responsive iRGD NIR-AZA 3 (10.5 nmol) over time (n ¼ 4). (a) Plot of TBR values at
individual time-points over 96 h, dashed red line indicating threshold value of 2. Values determined by ROI total fluorescence signal of tumour
divided by an averaged value of three independent background regions as measured by living image software v4.7. (b) Plot of tumour (solid trace)
and averaged background (dashed trace) fluorescence intensity over 96 h. (c) Representative in vivo fluorescence images of 3 using a MDA-MB
231 subcutaneous tumourmodel at different time points (scale bar identical to Fig. 8 and 10). First image shows selected tumour ROI (solid circle)
and three background ROIs (dashed circles).























































































View Article Onlineabout due to an initial distribution through normal and
cancerous tissues followed by a faster clearance of 10 from
normal tissue with retention within cancerous tissue. The
sequence of images shown in Fig. 7c illustrates the general
challenge facing always-on uorophores, regardless of whether
they are substituted with cancer specic targeting agents or not.Fig. 10 Analysis of in vivo fluorescence imaging for bio-responsive PEGN
time-points over 96 h, dashed red line indicating threshold value of 2. Valu
averaged value of three independent background regions asmeasured by
background (dashed trace) fluorescence intensity over 96 h. (c) Represe
taneous tumour model at different time points (scale bar identical to
background ROIs (dashed circles).
6952 | Chem. Sci., 2019, 10, 6944–6956As the process of accumulation and clearance of uorophore
from normal and cancerous tissues are both dynamic processes,
the success or failure of an always-on probe relies on identifying
the time point at which uptake and clearance for the different
tissue types are most divergent from each other. This poses
signicant challenges for their use in surgical oncologicalIR-AZA 1 (3.7 nmol) over time (n¼ 4). (a) Plot of TBR values at individual
es determined by ROI total fluorescence signal of tumour divided by an
living image software v4.7. (b) Plot of tumour (solid trace) and averaged
ntative in vivo fluorescence images of 1 using a MDA-MB 231 subcu-
Fig. 8 and 9). First image shows tumour ROI (solid circle) and three
This journal is © The Royal Society of Chemistry 2019
Fig. 11 Competitive bind studies using RGD 5 and RGD NIR-AZA 2 (n
¼ 4 pairs). (a) Plots of increasing tumour intensity over 3 h post
administration for 2 (red trace) and for 5 followed by 2 (black trace). (b)
Plots showing rate of increasing fluorescence for first 60 min post
administration for 2 (red trace) and for 5 followed by 2 (black trace). (c)
Imaging of resected tumours before and after dissection from animals
treated 2 and for 5 followed by 2.























































































View Article Onlinepractice with respect to patient-to-patient variances and
complex hospital scheduling.
Analysis of the image timelines for bio-responsive RGD NIR-
AZA 2 showed remarkable differences from control 10 (Fig. 8).
As 2 is administered in solution at pH 7.2, it is non-uorescent
and remained virtually uorescent silent within the vasculature
immediately post injection ((Fig. 8b), see Fig. S13 in ESI† for
additional time point images). At 60 min post injection, 2 begun
to accumulate at the tumour region and the uorescent signal
had turned on giving a measured TBR of 1.4, with some back-
ground also observed from the adjacent liver (Fig. 8a and c). By
3 h a signicant 4.1-fold increase in tumour uorescence
intensity had occurred along with a jump in TBR, surpassing
the threshold of 2. The TBR value (2.5) reached a maximum at
6 h and maintained this level until 24 h. Importantly, emission
intensity from the tumour reached a maximum within 3 h andThis journal is © The Royal Society of Chemistry 2019there was no reduction in intensity between 3 and 6 h coin-
ciding with when the TBR was at its maximum (Fig. 8b and
inset). Encouragingly, even at 9 h only a 20% intensity
reduction had occurred which provides a wide time frame in
which tumour visualisation could be achieved (Fig. 8a). The
ability of 2 to effectively tumour stain shortly aer administra-
tion can be judged by the sequence of images shown in Fig. 8c.
This we view very positively as not only is the threshold reached
quickly, it is maintained for a prolonged time. This ts well with
a clinical surgical workow whereby the contrast agent could be
administered at the start of surgery with intraoperative tumour
visualization possible.
Similarly, responsive iRGD NIR-AZA 3 also had emission
suppressed at the start of imaging with very low uorescence at
20 min and tumour accumulation evident at 60 min with a TBR
of 1.4 (Fig. 9c, see Fig. S14 in ESI† for additional time point
images). Between 20min and 3 h there was a 4.7-fold increase in
tumour uorescence intensity (Fig. 9b and inset). Yet, in
comparison to 2 the extent of background signal was larger,
though not brighter than the tumour itself and there was
a longer delay until 6 h before the TBR threshold reached 1.7
(Fig. 9a and c). Disappointingly, the TBR never exceeded the
threshold value of 2 with the best value of 1.8 recorded 48 h post
injection.
Finally, the pegylated bio-responsive 1 was studied to
determine the inuence of the conjugating group on the time
taken to reach maximum tumour uorescence and TBR. Again,
emission remained off in the beginning with a similar, but
considerably time delayed, prole to that of 2. TBRs remained
low (1.2) for the rst 60 min then rose to 1.6 and 1.8 at 6 and
9 h respectively. It took 9 h to reach maximum tumour uo-
rescence intensity with this level remaining relatively
unchanged at 24 h. Pleasingly, the TBR threshold of 2 was
reached at 24 h and this was maintained for a further 48 h.
Comparing the changing TBRs of pegylated 1 and RGD 2 over
time illustrates that substituting with the peptide sequence
provides a considerably faster tumour accumulation. If clini-
cally adopted, the slower time frame of 1 would most likely
require its administration 24 h before surgery, though its long
retention within the tumour may provide a prolonged window
in which it could be imaged.
To complete this study, further in vivo tests were performed
on the most promising derivative RGD NIR-AZA 2. To gain
insight into the initial rate of tumour uorescence turn on,
images were acquired every 10 min for 3 h immediately aer
introduction of 2. To establish that the RGD substituent was
inuencing the rate of tumour uptake, competitive binding or
blocking experiments were also carried out. Experimentally this
was achieved by rst administering an i.v. tail injection of the
RGD peptide 5 (6.8 fold equivalence excess) and following
a short time period (5 min) 2 was then administrated. It would
be expected that the rst administration of RGD 5 would result
in the integrin receptors being bound by the free peptide such
that when NIR-AZA 2 was next introduced there would be
a reduced uorophore uptake and as such a lower switch-on of
uorescence. In order to make direct comparisons, pairs of
mice with closely matching sized tumours were selected forChem. Sci., 2019, 10, 6944–6956 | 6953























































































View Article Onlineeach experiment (n¼ 4 pairs). One animal was rst given RGD 5
then both animals were administered with 2, following which
uorescence images of both animals were taken every 10 min
for the following 3 h. Averaged results from four experiment
showed a 1.75 fold reduction in the total tumour uorescence
intensity aer three hours for the mice which were rst treated
with the peptide 5 prior to receiving the NIR-AZA conjugate 2
versus the mice which only received 2 (Fig. 11a).
Additionally, the rate of uorescence turn on in the rst
80 min within the tumour that was not exposed to free RGD
peptide was 1.9-fold higher than that exposed to the competing
peptide (Fig. 11b). These results conrm that the peptide
substituent of the RGD-uorophore 2 is positively inuencing
tumour accumulation immediately following administration,
which facilitates early time point imaging. Upon completion of
imaging, tumours were resected from an animal pair with
quantication of their uorescence intensities showing a 3.9
fold suppression of emission intensity from the RGD peptide
pre-treated animal (Fig. 11c and S15†). Encouragingly, dissec-
tion and imaging of the tumours showed that the uorescence
intensity was highest at the outer boundary of the tumour,
which would be most benecial for operative identication of
the full extent of tumour margins (Fig. 11c). Finally, analysis of
the uorescence turn on prole of 2 alone showed that intensity
had reached a near maximum at 80 min (Fig. 11a and b red
traces). This indicates that 2 could be administered at the start
of a surgical procedure with intraoperative tumour visualization
taking place without signicantly impeding the normal surgical
workow.
Conclusion
In summary, three bio-responsive NIR-AZA uorophore
constructs have been synthesised conjugated to either active
(RGD) or passive (PEG) tumour targeting groups and their
photochemical, cellular and in vivo properties compared with
an always-on uorescent control. Each bio-responsive derivative
showed excellent off to on uorescence switching characteris-
tics with large enhancement values. In vitro live MDA-MB 231
cell imaging experiments showed internal acidic organelle cell
staining with the responsive probes 2 and 3, contrasting with
the always-on derivative 10 which rst showed plasma
membrane before internal organelle staining. This result proves
that the delity of uorescence switching is maintained in
cellular experiments and is independent of the conjugating
group.
A comprehensive in vivo assessment of tumour imaging
performance for bio-responsive probes 1, 2, 3 and always-on
derivative 10 was conducted with monitoring of the uores-
cence distributions over 96 h following administration. As
anticipated, the always-on 10 gave an immediate, non-specic
and very strong emission prole throughout animals whereas
the bio-responsive 1, 2 and 3 displayed relatively very low initial
uorescence. In the case of 10, clearance from normal tissue
with accumulation and retention in tumour, allowed for a TBR
above 2 to be reached between 9 and 24 h. All three bio-
responsive derivatives switched on within tumours at time6954 | Chem. Sci., 2019, 10, 6944–6956points consistent with their conjugated targeting groups. cRGD
2 and iRGD 3 both had effective switch-on in the rst hour
though 2 had superior specicity for tumour than 3. Probe 2
achieved the threshold TBR value of above 2 within 3 h and this
was maintained for a further 24 h. Relatively, the PEGylated 1
had slower similar turn on characteristics taking 9 h to reach
maximum uorescence from the tumour. Despite the slower
accumulation, its retention was biased to the tumour tissue
with the threshold TBR value being reached at 24 h and main-
tained out to 96 h. The side-by-side imaging comparison of 1
and 2 is an important and unique illustration of the dynamic
differences between passive EPR and active targeting in action.
Overall, the cRGD-conjugate 2 has been identied as
showing excellent potential for clinical translation for intra-
operative uorescence guided tumour margin identication. Its
bio-responsive nature with early accumulation at the tumour
periphery may overcome the inherent drawback of always-on
uorophores requiring prolonged clearance times. The PEGy-
lated derivative 1 does also offer potential for clinical trans-
lation though its slow switch-on rate may ultimately limit its
clinical scope.
The next ongoing stage of this research is to record contin-
uous NIR-uorescence video of the bio-responsive turn on at
tumour margins to gather more kinetic data on the tissue
dependent rates of emission increase over the rst 90 min. This
real-time data will be utilised in conjunction with specically
developed algorithms for dynamic image analysis that could
provide the surgical team with an augmented reality (AR) heat
map representation of the tissue to be excised during the
operation. An intraoperative use of dynamic uorescence tissue
imagery combined with AI analysis and a clinical AR interface
has the potential to transform surgical practice.Experimental section
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